Drugs / TPIV100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04197687 | Feb 2020 → Jan 2025 | breast adenocarcinoma | Academic and Community Cancer Research United | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPIV100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04197687 ↗ |
| Modality | Vaccine | “TPIV100 is a type of vaccine made from HER2 peptide” NCT04197687 ↗ |
| Route | Other | “Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive TPIV100 intradermally (ID) and sargramostim ID on day 1.” NCT04197687 ↗ |